It appears that the rapid washout of PSMA ligands from ccRCC lesions may result from PSMA expression in the ECs of the neo-vasculature rather than directly in cancer cells and may be a factor that hinders the treatment of RCC with PSMA-labeled ligands due to the lower radiation doses absorbed by the cancer cells. The gene discussed is FOLH1; the disease is cancer.